Hospitalized COVID-19 Patients with High Levels of Soluble Urokinase Receptor (suPAR) are at Higher Risk for Kidney Injury, Study Suggests According to a new observational study led by the researchers of Michigan Medicine - University of Michigan have reported that COVID-19 patients in hospital exhibit high levels of soluble urokinase receptor (suPAR). SuPAR is an immune-derived pa... https://www.coherentmarketinsights.com/news/hospitalized-covid-19-patients-with-high-levels-of-soluble-urokinase-receptor-supar-are-at-higher-risk-for-kidney-injury-study-suggests-211